Exclusive Summary

• Planned for US FDA ANDA filing in 2027, offering a first-wave generic or Paragraph IV challenge advantage to secure early entry into the high-barrier JAK inhibitor market.
• Full dosage coverage of 15mg/30mg/45mg aligns precisely with the multi-billion dollar originator market for Rheumatoid Arthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.
• Mastering the complex Sustained-release (SR) formulation under FDA cGMP standards provides a strong quality endorsement for rapid global expansion, especially in emerging or non-patent markets.
• Offers overwhelming cost-competitiveness against the expensive originator (over $6,000/month in the US), perfectly matching global payer cost-containment trends and national tender requirements.